All In Biotech

Drug Trial Radar · NCT06225973

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

A Phase 2b, Multicenter, Randomized, Double-masked Vehicle-controlled Study to Evaluate the Efficacy and Safety of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

880

Planned (sponsor's estimate)

Start

Feb 6, 2024

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

Conditions

  • Dry Eye Disease

Interventions

  • TL-925Drug

    TL-925 is an eye drop.

  • PlaceboOther

    The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of TL-925 compared to vehicle on tear productionTime frame: Baseline to Day 29

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea and Cataract Consultants of Arizona

    Phoenix, Arizona

  • Global Research Management

    Glendale, California

  • Nvision - La Mesa

    La Mesa, California

  • Nvision - Torrance

    Torrance, California

  • Wyse Eyecare

    Northbrook, Illinois

  • Pankratz Eye

    Columbus, Indiana

  • Butchertown Clinical

    Louisville, Kentucky

  • Andover Eye Associates - Andover

    Andover, Massachusetts

  • Andover Eye Associates - Raynham

    Raynham, Massachusetts

  • NEERA - Westborough

    Westborough, Massachusetts

  • NEERA - Woburn

    Woburn, Massachusetts

  • Oculus Research

    Garner, North Carolina

  • Wilmington Eye

    Leland, North Carolina

  • Scott and Christie EyeCare Associates

    Cranberry Township, Pennsylvania

  • Advancing Vision Research

    Goodlettsville, Tennessee

  • Total Eye Care, PA

    Memphis, Tennessee

  • Advancing Vision Research

    Smyrna, Tennessee

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.